Health TrialsbyHealthPanel

Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

2

Review clinical trials related to Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Available

Individual Patient Compassionate Use of Mirdametinib

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Trial details
Age: 2+Biological sex: AllType: Expanded AccessSponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyUpdated: Oct 5, 2026Locations: 2
Eligibility criteria

Patient has a serious, debilitating or life-threatening medical condition that c... [+1]

Read more
Status: Not yet recruiting

A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

The purpose of this study is to determine the safety, pharmacokinetic (PK), and tolerability of multiple treatment cycles of oral mirdametinib in infants and toddlers (0 to less than \[\<\] 24 months of age) with measurable neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PNs) that is symptomatic or asymptomatic but in a high-risk location with a high risk of morbidity.

Participants needed: 6
Trial details
Phase: Phase 1Age: 0-21Biological sex: AllType: InterventionalSponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyUpdated: Sep 30, 2026Locations: 1
Eligibility criteria

Age 1.1 Cohort 1: greater than (>) 12 to less than or equal to (<=) 21 months of... [+9]

Participant has family history of sudden cardiac death. [+5]

Read more